

# Indian Pharmaceutical Formulations Industry Report, 2008-2009



India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more than 400 kinds of API (Active Pharmaceutical Ingredient) and over 60,000 kinds of pharmaceutical formulations are available in Indian market, and 60% of API and 25% of patent medicine are exported.

In terms of the medical product value, India ranks at the fourteenth worldwide. Over half output of the top ten Indian pharmaceutical companies are exported to oversea markets each year, with a total value of US \$5.8 billion approximately.

Indian pharmaceutical formulations are mainly exported to the U.S.A, western Europe and Russia, are basically the generic drugs with expired patent, especially the primary ones such as Fluoxetine, Ciprofloxacin and Omeprazole etc. However, India also engaged in the innovations. For example, Lupin Laboratories self-developed the cefotaxime without infringing the patent of Takeda Pharmaceuticals.

Apart from the constant expansion in the U.S.A and European markets, Indian pharmaceutical companies also target on the new markets such as China, Japan, Brazil and Mexico etc. in order to decentralize of market risks. According to the Mckinsey, the Indian pharmaceutical market value will reach as high as US \$25 billion in 2010.

India has numerous talented scientists who specialized in the chemicals and pharmaceutical. It has close contact with the FDA and other international supervision institutions. Furthermore, it also has high-quality pharmaceutical production facilities. Compared to the developed countries, it is easier for India to conduct the clinical trial and also a lower cost. India also has strong IT capability to support the clinical data management.

The labor cost in India is 70% lower than in the U.S.A. The expenditure for establishing a pharmaceutical factory with FDA approval in India is only 70% of that in the U.S.A. The multinational pharmaceutical companies have already outsourced the API, intermediates and generic drugs production to India and China etc.

# Table of Contents

- **1. Overview of Pharmaceutical Formulations Industry in India**
- 1.1 Introduction to Pharmaceutical Formulations
- 1.2 Current Status and Prospects of Global Pharmaceutical Formulations Industry
- 1.3 Current Status and Prospects of Indian Pharmaceutical Formulations Industry
- **2. Analysis on Major Pharmaceutical Formulations Producers in India**
- 2.1 Ranbaxy Laboratories Ltd
- 2.2 Dr Reddys Laboratories Ltd
- 2.3 Cipla Ltd
- 2.4 Sun Pharmaceuticals Industries Ltd
- 2.5 Piramal Healthcare Ltd
- 2.6 Wockhardt Ltd
- 2.7 Cadila Healthcare Ltd
- 2.8 Matrix Laboratories Ltd
- 2.9 GlaxoSmithkline Pharmaceutical Ltd
- 2.10 Torrent Pharmaceuticals Ltd
- 2.11 IPCA Laboratories Ltd
- 2.12 Pfizer Ltd
- 2.13 Alembic Ltd
- 2.14 Aventis Pharma Ltd
- 2.15 Panacea Biotec Ltd
- 2.16 Strides Arcolab Ltd
- 2.17 Unichem Laboratories Ltd
- 2.18 Emami Ltd
- 2.19 Novartis India Ltd
- 2.20 Abbott India Ltd
- 2.21 JB Chemicals & Pharmaceuticals Ltd
- 2.22 Elder Pharmaceuticals Ltd
- 2.23 FDC Ltd
- 2.24 Wyeth Ltd
- 2.25 Natco Pharma Ltd
- 2.26 Ajanta Pharma Ltd
- 2.27 Astrazeneca Pharma India Ltd
- 2.28 Twilight Litaka Pharma Ltd
- 2.29 Granules India Ltd
- 2.30 TTK Health Care Ltd
- **3. Pharmaceutical Competitiveness Contrast between India and China**

- 3.1 Contrast of Industrial Status Quo
- 3.2 Contrast of R&D
- 3.3 Contrast of Product Structure
- 3.4 Contrast of International Certification
- 3.5 Contrast of International Market Exploitation

# Selected Charts

- Value of drugs going off patent in the world.2006-2011
- Revenue and net profit of Ranbaxy.2003-2007
- Business model of Ranbaxy,2007
- Global operation of Ranbaxy,2007
- Europe-Key Markets of Ranbaxy,2007
- Emerging markets of Ranbaxy,2007
- Geographic sales split of Ranbaxy, 2007
- Inorganic strategy of Ranbaxy,2007
- Aspirations of Ranbaxy (2012)
- Revenue and net profit of Dr. Reddy, 2003-2007
- Consolidated Business-Wise Performance of Dr. Reddy
- Geographic Mix of Formulations of Dr. Reddy
- Therapy-wise distribution (based on FY 05-06 performance)
- Revenue and net profit of Sun Pharmaceuticals,2004-2008
- Products structure of Sun Pharmaceuticals, 2009
- Ranks based on prescription share of Sun Pharmaceuticals
- Revenue composition of Sun Pharmaceuticals,2009
- Growing revenue of Sun Pharmaceuticals,2003-2007
- Sustained profitability of Sun Pharmaceuticals,2003-2007
- Successful acquisitions of Sun Pharmaceuticals,1995-2003
- Peer comparison of Sun Pharmaceuticals,1992-2007
- Strategy and approach of Sun Pharmaceuticals,2009
- Revenue and net profit of Piramal,2004-2008

- Branded Formulations—Consolidated Q3-FY2009
- Brands holding by Piramal,2009
- Drug life-cycle of Piramal,2009
- Manufacturing market of Piramal,2009
- Global outsourcing partner,2009
- Strategy of Piramal,2009
- Revenue and net profit of Wockhardt.2003-2007
- Biopharmaceuticals value chain of Wockhardt,2008
- Sales Revenues and Profits of Wockhardt,1992-2007
- Global operations of Wockhardt,2008
- Operation distribution of Wockhardt in 1992, 2000 and 2007
- Balanced portfolio of Wockhardt,2008
- Eight acquisitions of Wockhardt,1997-2007
- Revenue and Net Profit of Cadila from 2004 to 2008
- Revenue break-up of Cadila
- financial highlights of Cadila, 2005 -2008
- Research focus of Cadila
- Strong brand of Cadila
- Scheme of Cadila for 2009
- Strategies for growth momentum of Cadila
- Revenue and Net Profit of Matrix,2004-2008
- Capacities and production of Matrix,2006-2007
- Three principal products of Matrix,2007
- Shareholding pattern of Matrix, 2008
- Product group-wise performance of Matrix
- Revenue and Net Profit of GlaxoSmithkline,2004-2008

- Current Products of GlaxoSmithKline
- New Pharma Products
- Net Sales of GlaxoSmithkline (by price category) ,2007-2008
- Net Sales of GlaxoSmithkline (by segments) ,2007-2008
- Revenue and net profit of Torrent, 2004-2008
- Information in case of imported technology, 2005-2007
- Therapeutic area sales of Torrent, 2006-2007
- Sales of Torrent Pharmaceuticals by regions, 2006-2008
- Revenue and Net Profit of IPCA , 2004-2008
- Financial highlights of IPCA from 1998 to 2008
- Break-up of pharmaceutical sales of IPCA (by products)
- Domestic branded formulations groupwise contribution of IPCA,2007-2008
- Continentwise exports of IPCA
- Distribution of Shareholding of IPCA as on March 31,2008
- Revenue and Net Profit of Pfizer, 2004-2008
- Revenue and net profit of Alembic,2004- 2008
- New products lauched in respetive therapy segment of Alembic
- Key products of animal-health of Alembic
- Distribution of shareholding of Alembic
- Contribution to tatal domestic formulation sales of Alembic
- Financial highlight of Alembic, 2007-2008
- Sales and income from operations
- Revenue and net profit of Aventis,2004- 2008
- The break up of Net Sales
- Revenue and net profit of Panacea Biotec,2004 -2008
- Brand standing and market share of Panacea

- Shareholding pattern of Panacea as on March 31, 2008
- Gross turnover of Panacea for the financial year 1997, 2002 and 2007
- Strategy of Panacea
- Revenue and net profit of Strides from 2004 to 2008
- Business model of Strides
- Revenue attributable to location of customers of Strides
- Revenue Geographical distribution of Strides for 2008
- Strategy of Strides
- Revenue and net profit of Unichem, 2004-2008
- Comparison of power brands of Unichem, 2006-2008
- Shareholding pattern as on March 31, 2008
- Financial highlights of Unichem, 2005-2008
- Operational statement of Emami
- Snapshot of Emami's power brands
- Highlights of Emami for the financial year 2008
- Revenue and earnings performance of Emami from 2004 to 2008
- Peer group valuation for financial year 2008
- Strategy of Emami
- Revenue and net profit of NIL, 2004 - 2008
- Product sales of NIL in 2008
- Sales of Pharmaceutical products by regions, 2008
- Products launched by NIL in 2008
- Existing Emerging Markets for NIL
- NIL's Consistent strategy for 2009
- Revenue and net profit of Abbott, 2004 - 2008
- Sales of Pharmaceutical Formulations of Abbott in 2008



- Revenue and net profit of JBCPL, 2004 - 2008
- JBCPL Composition of Sales (Formulations & APIs)
- JBCPL Composition of Sales (Formulations & APIs)
- Status of JBCPL Product Registrations
- Revenue and net profit of Elder from 2004 to 2008
- Products of Elder
- The main financial data of Elder
- Stocks and sales of finished goods of Elder
- Revenue and assets of Elder, 2007-2008
- The main financial data of FDC, 2007 - 2008
- Revenue and assets of FDC
- Revenue and net profit of Wyeth, 2004- 2008
- Revenue and net profit of Natco, 2004-2008
- Shareholding pattern of Natco
- Revenues of Natco by divisions, 2006-2008
- Revenue and net profit of Ajanta, 2007-2008
- Segment Wise Revenue, Results and Capital Employed of AstraZeneca
- Revenue and net profit of Twilight, 2007 -2008
- Revenue and net profit of Granules, 2004 -2008
- Financial analysis of Granules in 2007-2008
- Growing API and PFI business of Granules
- Geographic break-up of revenues from key markets of Granules in 2007-2008
- Budget measures of Granules
- Revenue and net profit of TTK, 2007-2008
- Segmentwise revenue and results of TTK, 2006- 2008

# How to Buy

Product details			How to Order
Single user	USD	File	By email: report@researchinchina.com
	999	PDF	By fax: 86-10-82600829
	1,499	PDF	By online: www.researchinchina.com
Publication date: Apr. 2009			
For more information, call our office in Beijing, China:			
Tel: 86-10-82600828			
Website: www.researchinchina.com			